Journey Medical Corporation (NASDAQ:DERM) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET

Company Participants

Jaclyn Jaffe - Senior Director, Corporate Operations
Claude Maraoui - Co-Founder, President and CEO
Joseph Benesch - Interim Chief Financial Officer
Dr. Srinivas Sidgiddi - Vice President, Research and Development
Ramsey Allous - General Counsel and Corporate Secretary

Conference Call Participants

Scott Henry - ROTH Capital
Andy Fleszar - B. Riley

Operator

Ladies and gentlemen, thank you for standing by. Good afternoon. And welcome to Journey Medical’s Third Quarter 2023 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions]

Participants of this call are advised that the audio conference call is being broadcast live over the internet and is also being recorded for playback purposes. A webcast replay of the call would be available for approximately one hour after the end of the call for approximately 30 days.

I would now like to turn the call over to Jaclyn Jaffe, the company’s Senior Director of Corporate Operations. Please go ahead, Jacklyn.

Jaclyn Jaffe

Good afternoon and thank you for participating in today’s conference call. Joining me from Journey Medical Corporation’s leadership team are, Claude Maraoui, Co-Founder, President and Chief Executive Officer; Joseph Benesch, Interim Chief Financial Officer; Dr. Srinivas Sidgiddi, Vice President of Research and Development; and Ramsey Allous, General Counsel and Corporate Secretary, who will be joining for the Q&A portion of the call.

During this call, management will be making forward-looking statements, including statements that address among other things, Journey Medical’s expectations for future performance, operational results, financial condition and the receipt of regulatory approvals.

Forward-looking statements involve risks and other factors that may cause actual results to differ materially from those statements. For more information about these risks, please refer to the risk factors described in Journey Medical’s most recently filed periodic report on Form 10-K and Form 10-Q, the Form 8-K filed with the SEC today and the company’s press release that accompanies this call, particularly the cautionary statements in it.

Today’s conference call includes non-GAAP financial measures that Journey Medical believes can be useful in evaluating its performance. You should not consider this additional information in isolation or as a substitute for results prepared in accordance with GAAP.

For a reconciliation of this non-GAAP financial measure to net loss, its most directly comparable GAAP financial measure, please see the reconciliation table located in the company’s earnings press release.